glp 1 and antipsychotics New Weight Loss Drugs in Psychiatry GLP-1 Receptor Agonists Improve Metabolic

To assess the time-to-event data for achieving clinically significant weight loss, Kaplan-Meier survival analysis was performed, comparing the time to reach 5%, 10%, and 15% weight loss between the engaged and nonengaged groups

Not intended for those under the age of 18

Due to their remarkable ability to regulate metabolism, they have been widely adopted in the management of type 2 diabetes mellitus (T2DM) and obesity

The absence of population-level epidemiological data does not make this a theoretical concern

Biologic agents targeting specific inflammatory pathwaysincluding TNF- inhibitors (adalimumab, etanercept), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and B-cell depleting agents (rituximab)provide additional options for patients with inadequate response to conventional therapy